A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis

StatusCompleted
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified Show 7 more changesShow less
    • Results posted: Oct 16, 2026
    • Trial completed
    • Trial arms changed: 5 → 4
    • Study completion date changed from estimate of Aug 2026 to Jul 16, 2026
    • Eligibility criteria expanded, about 18 words
    • Secondary endpoints: 10 to 5
    • Site details revised at 12 of 46 sites
  2. Primary completion date changed from estimate of Sep 2025 to Sep 25, 2025v17
  3. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 430 to confirmed 301
    • Site details revised at 46 of 46 sites
    v16
  4. Primary completion date: Dec 2025 to Sep 2025
    • Study completion date: Nov 2026 to Aug 2026
    v15
  5. 2 versions Re-verified since Apr 18, 2025, no change to tracked fieldsv13-v14
Show 11 earlier versionsHide 11 earlier versions
  1. Primary endpoints: 2 to 4
    • Secondary endpoints: 8 to 10
    • Eligibility criteria expanded, about 5 words
    v12
  2. Study sites: 47 to 46v11
  3. Site details revised at 1 of 47 sitesv10
  4. Study sites revised (47)v9
  5. Site details revised at 1 of 47 sitesv8
  6. Site details revised at 1 of 47 sitesv7
  7. Study sites revised (47)v6
  8. Study sites: 45 to 47v5
  9. Site details revised at 8 of 45 sitesv4
  10. Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Study sites: 43 to 45
    • Primary completion date: Dec 17, 2025 to Dec 2025
    • Study completion date: Nov 4, 2026 to Nov 2026
    • Start date changed from estimate of May 6, 2024 to Apr 24, 2024
  11. Study sites: 47 to 43v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eli Lilly
363 trials monitored
See 16 trials at risk
Atopic Dermatitis
500 trials monitored
See 18 trials at risk
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab with/without Topical Corticosteroid Treatment in Participants with Moderate-to-Severe Atopic Dermatitis. The study will last approximately 62 weeks.
Trial Details
NCT Number NCT06280716
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Atopic Dermatitis
Related terms Dermatitis, Atopic
Enrollment 301 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov